Journal: Frontiers in Pharmacology
Article Title: LITAF suppresses breast cancer and paclitaxel resistance by ubiquitinating and degrading PCMT1 to inhibit COX-2-dependent arachidonic acid metabolism
doi: 10.3389/fphar.2026.1706420
Figure Lengend Snippet: PCMT1 is involved in PTX resistance of BC cells, a process potentially involving COX-2-mediated AA metabolism. (A) RT-qPCR analysis of PCMT1 mRNA levels in tumor tissues and paired adjacent normal tissues from 30 BC patients treated with PTX. (B) Immunoblotting analysis of PCMT1 and COX-2 protein levels in tumor tissues and paired adjacent normal tissues from PTX-treated BC patients (n = 10; 5 PTX-sensitive and 5 PTX-resistant). (C) Correlation between PCMT1 and COX-2 expression was assessed using the Pearson correlation coefficient. (D) RT-qPCR analysis of PCMT1 mRNA levels in MCF10A, BC cells (MDA-MB-231, MCF-7), and PTX-resistant cells (MDA-MB-231/PTX, MCF-7/PTX) (n = 3). (E) Immunoblotting analysis of PCMT1 and COX-2 protein levels in BC cells and PTX-resistant cells (n = 3). (F) IC50 values of BC cells and PTX-resistant cells assessed using the CCK-8 assay (n = 3). Values are represented as mean ± SD. * p < 0.05, ** p < 0.01, *** p < 0.001.
Article Snippet: Human normal mammary epithelial cells MCF10A (ATCC, USA) were cultured in DMEM/F12 (Procell) supplemented with HS (5%), EGF (20 ng/mL), hydrocortisone (0.5 μg/mL), insulin (0.5 μg/mL), NEAA (1%), and P/S (1%).
Techniques: Quantitative RT-PCR, Western Blot, Expressing, CCK-8 Assay